| Thyroid carcinoma
Gavreto vs Tirosint SOL
Side-by-side clinical, coverage, and cost comparison for thyroid carcinoma.Deep comparison between: Gavreto vs Tirosint with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTirosint has a higher rate of injection site reactions vs Gavreto based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tirosint but not Gavreto, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gavreto
Tirosint
At A Glance
Oral
Once daily
RET kinase inhibitor
Oral
Daily
Thyroid hormone (synthetic T4)
Indications
- Metastatic Lung Non-Small Cell Carcinoma
- Thyroid carcinoma
- Hypothyroidism
- Thyroid carcinoma
Dosing
Metastatic Lung Non-Small Cell Carcinoma, Thyroid carcinoma 400 mg orally once daily on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after); continue until disease progression or unacceptable toxicity.
Hypothyroidism Once daily oral dose on empty stomach, 15 minutes before breakfast; adults start at 1.6 mcg/kg/day (lower in cardiac or geriatric patients), titrate by 12.5-25 mcg every 4-6 weeks; pediatric dosing weight-based by age (1.6-15 mcg/kg/day), titrated every 2 weeks; pregnant patients may require increased dose monitored every 4 weeks.
Thyroid carcinoma Once daily oral dose; dosage based on target level of TSH suppression for the stage and clinical status of well-differentiated thyroid cancer.
Contraindications
—
- Hypersensitivity to glycerol (inactive ingredient in TIROSINT-SOL)
- Uncorrected adrenal insufficiency
Adverse Reactions
Most common (>=25%) Musculoskeletal pain, constipation, hypertension, diarrhea, fatigue, edema, pyrexia, cough
Serious ILD/Pneumonitis, hypertension, hepatotoxicity, hemorrhagic events, tumor lysis syndrome, impaired wound healing, embryo-fetal toxicity
Most common Fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating, headache, hyperactivity, nervousness, anxiety, irritability, insomnia, tremors, muscle weakness, palpitations, tachycardia, diarrhea, vomiting, abdominal cramps, hair loss, flushing, rash, decreased bone mineral density, menstrual irregularities, impaired fertility
Serious Arrhythmias, increased blood pressure, heart failure, angina, myocardial infarction, cardiac arrest, seizures (rare); pseudotumor cerebri and slipped capital femoral epiphysis in pediatric patients
Hypersensitivity Urticaria, pruritus, skin rash, flushing, angioedema, abdominal pain, nausea, vomiting, diarrhea, fever, arthralgia, serum sickness, wheezing
Pharmacology
Pralsetinib is a kinase inhibitor of wild-type RET and oncogenic RET fusions and mutations (IC50s <0.5 nM), blocking downstream signaling pathways that drive uncontrolled tumor cell proliferation in RET fusion-positive NSCLC and thyroid cancer.
Synthetic T4 hormone (levothyroxine sodium) that exerts physiologic effects through control of DNA transcription and protein synthesis by binding thyroid receptor proteins attached to DNA in cell nuclei; the predominant active form T3 is derived approximately 80% from peripheral deiodination of T4, and oral levothyroxine maintains normal T4 levels when endogenous production is deficient.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gavreto
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Tirosint
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Gavreto
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Tirosint
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Gavreto
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tirosint
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tirosint.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GavretoView full Gavreto profile
TirosintView full Tirosint profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.